Lantern Pharma says EMA clears Phase 1b/2 LP-184 bladder cancer trial

• Lantern Pharma’s investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in biomarker-selected advanced bladder cancer cleared by the EMA.
• Study at Rigshospitalet in Copenhagen targets relapsed or refractory metastatic urothelial carcinoma; planned enrollment up to 39 patients.
• Primary endpoint is objective response rate under RECIST 1.1; dual selection uses PTGR1 overexpression with DNA-damage-repair deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260728012034) on July 28, 2026, and is solely responsible for the information contained therein.